Skip to content
2000
Volume 31, Issue 18
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Background: Almost all chronic liver diseases cause fibrosis, which can lead to cirrhosis and eventually liver cancer. Liver fibrosis is now considered to be a reversible pathophysiological process and suppression of fibrosis is necessary to prevent liver cancer. At present, no specific drugs have been found that have hepatic anti-fibrotic activity. Objective: The research progress of anti-hepatic fibrosis compounds in recent ten years was reviewed to provide a reference for the design and development of anti-hepatic fibrosis drugs. Methods: According to the structure of the compounds, they are divided into monocyclic compounds, fused-heterocyclic compounds, and acyclic compounds. Results: In this article, the natural products and synthetic compounds with anti-fibrotic activity in recent ten years were reviewed, with emphasis on their pharmacological activity and structure-activity relationship (SAR). Conclusion: Most of these compounds are natural active products and their derivatives, and there are few researches on synthetic compounds and SAR studies on natural product.

Loading

Article metrics loading...

/content/journals/cmc/10.2174/0929867331666230727102016
2024-06-01
2025-05-05
Loading full text...

Full text loading...

/content/journals/cmc/10.2174/0929867331666230727102016
Loading

  • Article Type:
    Review Article
Keyword(s): chronic liver diseases; cirrhosis; collagen I; HSC; Liver fibrosis; SAR
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test